How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership
Tóm tắt
Over the last decade there has been considerable research into the treatment, management, and quality of life of people living with multiple myeloma. However, there has been limited investigation into topics deemed important to patients and caregivers within this community. We conducted a James Lind Alliance Priority Setting Partnership to establish the ‘Top 10 Priorities for Myeloma Research’, informed by patient and public partners. A research team and steering group were established in 2019 to conduct the myeloma priority setting partnership. Steering group members included patients, caregivers, and healthcare providers who advised the research team and oversaw the scope of the project, grounded on their lived experience. Following the James Lind Alliance guidelines for identification and ranking of research questions, we used surveys and a virtual workshop to collect and prioritize questions posed by myeloma patients, caregivers, and healthcare providers across Canada. The Top 10 list of priorities for myeloma research was finalized at the consensus-building workshop and encompassed questions related to diagnosis, treatment, management, and living well with myeloma. A final participant evaluation survey elicited a positive response. The myeloma priority setting partnership identified the research priorities of people living with myeloma, caregivers, and healthcare providers to inform clinical research on this disease going forward. This project underscores the importance of patient and public engagement in the identification of research questions, highlighting the concerns of people affected by myeloma to ultimately improve the lives of people living with this disease. Research on multiple myeloma, a rare blood cancer, rarely focuses on topics that are personally important to people living with myeloma, their caregivers, and their healthcare providers. The purpose of this study was to complete a priority setting partnership, following guidelines from the James Lind Alliance, to identify unanswered research questions from people directly affected by myeloma. The project was guided by a steering group of people living with myeloma, their caregivers, and healthcare providers who informed all stages of this process including two questionnaires to collect and rank questions and a priority setting workshop. The workshop brought together representatives from each group to form the final ‘Top 10 Priorities for Myeloma Research’, which included questions related to diagnosis, treatment, management, and living well with myeloma. This process allowed us to identify the research priorities of the myeloma community and highlighted the importance of including patients and the public as team members in the research process. We encourage other myeloma researchers to do the same to ensure research is meaningful and relevant to the communities who rely on it.
Tài liệu tham khảo
Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020;25(9):e1406–13.
Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22:5428–33.
van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–27.
Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22(22):5419–27.
Partridge N, Scadding J. The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials. Lancet. 2004;364(9449):1923–4.
Chalmers I, Atkinson P, Fenton M, Firkins L, Crowe S, Cowan K. Tackling treatment uncertainties together: the evolution of the James Lind Initiative, 2003–2013. J R Soc Med. 2013;106(12):482–91.
Cuthbert C, Nixon N, Vickers M, Samimi S, Rawson K, Ramjeesingh R, et al. Top 10 research priorities for early-stage colorectal cancer: a Canadian patient-oriented priority-setting partnership. CMAJ Open. 2022;10(1):E278–87.
Klotz R, Holze M, Dörr-Harim C, Grohmann E, Nied B, Lebert B, et al. Top 10 research priorities in colorectal cancer: results from the colorectal cancer priority-setting partnership. J Cancer Res Clin Oncol. 2023;149(4):1561–8.
Aldiss S, Fern LA, Phillips RS, Callaghan A, Dyker K, Gravestock H, et al. Research priorities for young people with cancer: a UK priority setting partnership with the James Lind Alliance. BMJ Open. 2019;9(8):e028119.
Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 2000;355(9220):2037–40.
Crowe S, Fenton M, Hall M, Cowan K, Chalmers I. Patients’, clinicians’ and the research communities’ priorities for treatment research: There is an important mismatch. Res Involv Engag. 2015;1(1):1.
Tsang M, Le M, Ghazawi FM, Cyr J, Alakel A, Rahme E, et al. Multiple myeloma epidemiology and patient geographic distribution in Canada: a population study. Cancer. 2019;125(14):2435–44.
James Lind Alliance. The James Lind Alliance Guidebook [Internet]. 2021. Available from: www.jla.nihr.ac.uk
Fowler S, McLaughlin L, Bridges S, Robichaud M, Ridgway B, Reece D, et al. The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership. Br J Haematol. 2022;196(5):e52.
Oxford Blood Group. What matters most to people with multiple myeloma? Patient workshop outcomes [Internet]. 2022 Mar [cited 2023 Jul 12]. Available from: https://www.imm.ox.ac.uk/news/patient-priorities-guide-oxford-myeloma-research
Myeloma Canada. Myeloma Canada. 2022 [cited 2023 Jan 2]. Aldo Del Col Research Grant. Available from: https://myeloma.ca/en/clinical-trials-101-1/research-initiatives/aldo-del-col-research-grant
Jongsma K, van Seventer J, Verwoerd A, van Rensen A. Recommendations from a James Lind Alliance priority setting partnership—a qualitative interview study. Res Involv Engag. 2020;6(1):1–13.
Staley K, Crowe S, Crocker JC, Madden M, Greenhalgh T. What happens after James Lind Alliance priority setting partnerships? A qualitative study of contexts, processes and impacts. Res Involv Engag. 2020;6(1):1–10.
Fordham FT, Candy B, McMillan S, Thakrar S, Noble B, Best S. Does current palliative and end of life care research match the priorities of patients, carers and clinicians? A grant mapping analysis of the UK Clinical Research Collaboration’s Health Research Classification System dataset 2014. 2017.
Canadian Cancer Society. Our research strategy [Internet]. 2023 [cited 2023 Jul 16]. Available from: https://cancer.ca/en/research/our-research-strategy
Staley K, Crowe S, Crocker JC, Madden M, Greenhalgh T. What happens after James Lind Alliance priority setting partnerships? A qualitative study of contexts, processes and impacts. Res Involv Engag. 2020;6(1).
Gonzalez M, Ogourtsova T, Zerbo A, Lalonde C, Spurway A, Gavin F, et al. Patient engagement in a national research network: barriers, facilitators, and impacts. Res Involv Engag. 2023;9(1).
Martins Y, Lederman RI, Lowenstein CL, Joffe S, Neville BA, Hastings BT, et al. Increasing response rates from physicians in oncology research: a structured literature review and data from a recent physician survey. Br J Cancer. 2012;106:1021–6.
Sá MJ, Ferreira CM, Serpa S. Virtual and face-to-face academic conferences: comparison and potentials. J Educ Soc Res. 2019;9(2):35–45.
James Lind Alliance. Making a difference. 2020 [cited 2021 Aug 9]. Working with the priorities. Available from: https://www.jla.nihr.ac.uk/making-a-difference/working-with-the-priorities.htm
James Lind Alliance. Making a difference. 2020 [cited 2021 Aug 9]. Funded Research. Available from: https://www.jla.nihr.ac.uk/making-a-difference/funded-research.htm
Whiting C. Evidently Cochrane. [cited 2021 Aug 9]. Priority Setting Partnerships: celebrating 16 years of work to reduce research waste. Available from: https://www.evidentlycochrane.net/priority-setting-partnerships-celebrating-16-years-of-work-to-reduce-research-waste/
Canadian Frailty Network. Research and KT. 2018 [cited 2021 Aug 9]. 2018 Catalyst Grant Competition. Available from: https://www.cfn-nce.ca/research/our-research/our-portfolio-by-grant-type-or-competition/2018-catalyst-grant-program/